Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature

por Ge, Jennifer Y., Overmoyer, Beth
Publicado 2021

Copy Number Variation in Inflammatory Breast Cancer

por Hazra, Aditi, O’Hara, Andrea, Polyak, Kornelia, Nakhlis, Faina, Harrison, Beth T., Giordano, Antonio, Overmoyer, Beth, Lynce, Filipa
Publicado 2023

Inflammatory breast cancer appearance at presentation is associated with overall survival

por Balema, Wintana, Liu, Diane, Shen, Yu, El‐Zein, Randa, Debeb, Bisrat G., Kai, Megumi, Overmoyer, Beth, Miller, Kathy D., Le‐Petross, Huong T., Ueno, Naoto T., Woodward, Wendy A.
Publicado 2021

The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II–III and metastatic breast cancers

por Anderson, Karen S., Erick, Timothy K., Chen, Meixuan, Daley, Heather, Campbell, Margaret, Colson, Yolonda, Mihm, Martin, Zakka, Labib R., Hopper, Marika, Barry, William, Winer, Eric P., Dranoff, Glenn, Overmoyer, Beth
Publicado 2022

Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer

por Pernas, Sonia, Guerriero, Jennifer L., Naumenko, Sergey, Goel, Shom, Regan, Meredith M., Hu, Jiani, Harrison, Beth T., Lynce, Filipa, Lin, Nancy U., Partridge, Ann, Morikawa, Aki, Hutchinson, John, Mittendorf, Elizabeth A., Sokolov, Artem, Overmoyer, Beth
Publicado 2022

Prospective clinical experience with research biopsies in breast cancer patients

por Vaz-Luis, Ines, Zeghibe, Catherine A., Frank, Elizabeth S., Sohl, Jessica, Washington, Kimberly E., Silverman, Stuart G., Fonte, Joseph M., Mayer, Erica L., Overmoyer, Beth A., Richardson, Andrea L., Krop, Ian E., Winer, Eric P., Lin, Nancy U.
Publicado 2013

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer

por Tolaney, Sara M., Tan, Sally, Guo, Hao, Barry, William, Van Allen, Eliezer, Wagle, Nikhil, Brock, Jane, Larrabee, Katherine, Paweletz, Cloud, Ivanova, Elena, Janne, Pasi, Overmoyer, Beth, Wright, John J., Shapiro, Geoffrey I., Winer, Eric P., Krop, Ian E.
Publicado 2015

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer

por Waks, Adrienne G, Keenan, Tanya E, Li, Tianyu, Tayob, Nabihah, Wulf, Gerburg M, Richardson, Edward T, Attaya, Victoria, Anderson, Leilani, Mittendorf, Elizabeth A, Overmoyer, Beth, Winer, Eric P, Krop, Ian E, Agudo, Judith, Van Allen, Eliezer M, Tolaney, Sara M
Publicado 2022

Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer

por Garrido-Castro, Ana C., Regan, Meredith M., Niman, Samuel M., Nakhlis, Faina, Remolano, Claire, Rosenbluth, Jennifer M., Block, Caroline, Warren, Laura E., Bellon, Jennifer R., Yeh, Eren, Harrison, Beth T., Troll, Elizabeth, Lin, Nancy U., Tolaney, Sara M., Overmoyer, Beth, Lynce, Filipa
Publicado 2023

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer

por Stover, Daniel G., Gil Del Alcazar, Carlos R., Brock, Jane, Guo, Hao, Overmoyer, Beth, Balko, Justin, Xu, Qiong, Bardia, Aditya, Tolaney, Sara M., Gelman, Rebecca, Lloyd, Maxwell, Wang, Yu, Xu, Yaomin, Michor, Franziska, Wang, Vivian, Winer, Eric P., Polyak, Kornelia, Lin, Nancy U.
Publicado 2018

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study

por Barroso-Sousa, Romualdo, Keenan, Tanya E., Li, Tianyu, Tayob, Nabihah, Trippa, Lorenzo, Pastorello, Ricardo G., Richardson III, Edward T., Dillon, Deborah, Amoozgar, Zohreh, Overmoyer, Beth, Schnitt, Stuart J., Winer, Eric P., Mittendorf, Elizabeth A., Van Allen, Eliezer, Duda, Dan G., Tolaney, Sara M.
Publicado 2021

International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference

por Ueno, Naoto T., Espinosa Fernandez, Jose Rodrigo, Cristofanilli, Massimo, Overmoyer, Beth, Rea, Dan, Berdichevski, Fedor, El-Shinawi, Mohamad, Bellon, Jennifer, Le-Petross, Huong T., Lucci, Anthony, Babiera, Gildy, DeSnyder, Sarah M., Teshome, Mediget, Chang, Edward, Lim, Bora, Krishnamurthy, Savitri, Stauder, Michael C, Parmar, Simrit, Mohamed, Mona M, Alexander, Angela, Valero, Vicente, Woodward, Wendy A.
Publicado 2018

Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10(th) Anniversary Conference

por Woodward, Wendy A., Cristofanilli, Massimo, Merajver, Sofia D., Van Laere, Steven, Pusztai, Lajos, Bertucci, Francois, Berditchevski, Fedor, Polyak, Kornelia, Overmoyer, Beth, Devi, Gayathri R., Sterneck, Esta, Schneider, Robert, Debeb, Bisrat G., Wang, Xiaoping, van Golen, Kenneth L., El-Zein, Randa, Rahal, Omar M., Alexander, Angela, Reuben, James M., Krishnamurthy, Savitri, Lucci, Anthony, Ueno, Naoto T.
Publicado 2017

Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium

por Devi, Gayathri R., Hough, Holly, Barrett, Nadine, Cristofanilli, Massimo, Overmoyer, Beth, Spector, Neil, Ueno, Naoto T., Woodward, Wendy, Kirkpatrick, John, Vincent, Benjamin, Williams, Kevin P., Finley, Charlotte, Duff, Brandi, Worthy, Valarie, McCall, Shannon, Hollister, Beth A., Palmer, Greg, Force, Jeremy, Westbrook, Kelly, Fayanju, Oluwadamilola, Suneja, Gita, Dent, Susan F., Hwang, E. Shelley, Patierno, Steven R., Marcom, P. Kelly
Publicado 2019

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis

por Brastianos, Priscilla K., Strickland, Matthew R., Lee, Eudocia Quant, Wang, Nancy, Cohen, Justine V., Chukwueke, Ugonma, Forst, Deborah Anne, Eichler, April, Overmoyer, Beth, Lin, Nancy U., Chen, Wendy Y., Bardia, Aditya, Juric, Dejan, Dagogo-Jack, Ibiayi, White, Michael D., Dietrich, Jorg, Nayyar, Naema, Kim, Albert E., Alvarez-Breckenridge, Christopher, Mahar, Maura, Mora, Joana L., Nahed, Brian V., Jones, Pamela S., Shih, Helen A., Gerstner, Elizabeth R., Giobbie-Hurder, Anita, Carter, Scott L., Oh, Kevin, Cahill, Daniel P., Sullivan, Ryan J.
Publicado 2021

JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States

por Stevens, Laura E., Peluffo, Guillermo, Qiu, Xintao, Temko, Daniel, Fassl, Anne, Li, Zheqi, Trinh, Anne, Seehawer, Marco, Jovanović, Bojana, Alečković, Maša, Wilde, Callahan M., Geck, Renee C., Shu, Shaokun, Kingston, Natalie L., Harper, Nicholas W., Almendro, Vanessa, Pyke, Alanna L., Egri, Shawn B., Papanastasiou, Malvina, Clement, Kendell, Zhou, Ningxuan, Walker, Sarah, Salas, Jacqueline, Park, So Yeon, Frank, David A., Meissner, Alexander, Jaffe, Jacob D., Sicinski, Piotr, Toker, Alex, Michor, Franziska, Long, Henry W., Overmoyer, Beth A., Polyak, Kornelia
Publicado 2023